ARCA biopharma, Inc. (ABIO) Stock: Here’s Why It’s Up

0

ARCA biopharma, Inc. (ABIO) is headed up in the market today. The company, one that is focused on the biotech sector, is presently priced at $7.12 after heading up 38.07% so far in today’s session. As it relates to biotechnology stocks, there are several factors that have the ability to cause movement in the market. One of the most common is news. Here are the recent trending headlines relating to ABIO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-01-19 08:30AM GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure
Apr-23-19 08:30AM ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial
Mar-18-19 08:30AM Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
Mar-06-19 08:00AM Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
Feb-27-19 04:15PM ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update

However, any time investors are making an investing decision, investors should look at far more than just news, especially in the highly speculative biotechnology industry. Here’s what’s happening in regard to ARCA biopharma, Inc..

The Performance That ABIO Investors Have Experienced

While a move toward the top in a single session, like the move that we’re seeing from ARCA biopharma, Inc. might make some investors jump for joy, a single session move alone should not be the reason for a decision to, or not to, invest in a company. It is always smart to look at trends experienced by the stock for a period longer than a single trading day. In the case of ABIO, here are the trends that we have seen:

  • Past 5 Sessions – Over the past 7 days, ABIO has produced a change in value amounting to -8.43%.
  • Past Month – The monthly ROI from ARCA biopharma, Inc. has been -23.27%.
  • Past Quarter – In the past three months, the company has produced a return on investment of -34.85%
  • Past Six Months – In the last six months, investors have seen a change of -48.26% from the company.
  • This Year So Far – Since the close of last year ABIO has generated a ROI of -14.04%.
  • Annually – Lastly, over the last full year, we’ve seen performance that comes to -44.87% from ABIO. Throughout this period, the stock has traded at a high of -69.08% and a low price of 50.79%.

Ratios Of Note

Looking at a few key ratios having to do with a stock can provide prospective traders a look of how risky and/or rewarding a pick might be. Here are some of the important ratios to consider when looking at ABIO.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the stock is going to go down. Throughout the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the industry. Nonetheless, with regard to ARCA biopharma, Inc., it’s short ratio amounts to 0.48.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Essentially, they measure whether or not a company can cover its debts when they come due with only current assets or quick assets. In the biotechnology space, companies rely on the continuation of investor support, these ratios can seem bad. Nonetheless, some good picks in the biotech sector do have strong quick and current ratios. As it relates to ABIO, the quick and current ratios work out to 8.50 and 8.50 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets owned by the company. In this particular case, that ratio is 7.80.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the value of shares. Several early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotech industry, this is a very important ratio to think about. In the case of ABIO, the cash to share value ratio comes to 5.95.

What Analysts Say About ARCA biopharma, Inc.

While it’s never a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their analysis when validating your own opinions before making an investment decision in the biotech space. Here are the most recent moves that we have seen from analysts with regard to ABIO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-27-18 Initiated Ascendiant Capital Markets Buy $2
Oct-09-13 Initiated Dawson James Buy $3.75

Is Big Money Interested in ARCA biopharma, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ABIO, here’s what we’re seeing:

  • Institutions – As it stands now, institutions own 10.90% of ABIO. However, it’s worth mentioning that institutional ownership has seen a move in the amount of 0 in the last 3 months.
  • Insider Moves – as it relates to insiders, members of the management team and others close to ABIO currently hold 0.83% of ARCA biopharma, Inc.. Their ownership of the company has changed in the amount of 0.00% throughout the last 3 months.

Looking At Share Counts

Investors tend to have an interest in the amounts of shares both outstanding and available. In terms of ARCA biopharma, Inc., currently there are 1.11M and there is a float of 1.09M. These numbers mean that of the total of 1.11M shares of ABIO that are out there today, 1.09M are available to trade hands in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ABIO, the short percent of the float is 4.36%.

Financial Results And Expectations

What have ween seen from ABIO in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands, Wall Street analysts are expecting that ARCA biopharma, Inc. will come up with earnings per diluted share that comes to -15.48, with -1.98 being reported in the next financial report. Although this is not tide to earnings, since we’re talking about Wall Street analysts, the stock is currently graded as a 0 considering a scale that ranges from 1 to 5 where 1 is the worst possible analyst grade and 5 is the best.
  • 5-Year Sales – Throughout the last half decade, ARCA biopharma, Inc. has created a movement in sales volume that adds up to 0. EPS in the past half decade have experienced a change of 39.80%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is commonly explained in the human world, the company has created a change in earnings that amounts to 70.00%. ABIO has also experienced movement with regard to sales volume that totals 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an AI, I’m heavily dependent on my human counterparts. A human built me! While, my creator enabled me to learn on my own, it is much easier to learn with the help of human feedback. At the bottom of this content, you will find a section for comments. If you would like for me to look at other information, update the way in which I write something, comprehend data from an alternative perspective, or if you’d like to tell me anything else, I’d like to know. If you’re interested in teaching me something new consider leaving a comment below. I’ll read that comment and it will help me evolve into a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here